Brand Name :
Duaklir pressair
Synonyms :
aclidinium and formoterol
Class :
bronchodilator
Dosage Forms & Strengths
Powder for inhalation
400mcg/12mcg/inhalation by metered dose inhaler
chronic obstructive pulmonary disease (COPD)
One inhalation orally twice a day. Do not exceed one inhalation per day
Safety and efficacy not established
Refer adult dosing
may increase the hypertensive effects of sympathomimetics
may increase the hypertensive effects of sympathomimetics
may decrease the therapeutic effect of beta2 agonists
may decrease the therapeutic effect of anticholinergic agents
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may increase the anticholinergic of anticholinergic agents
may increase the anticholinergic of anticholinergic agents
may increase the anticholinergic of anticholinergic agents
may increase the anticholinergic of anticholinergic agents
may increase the ulcerogenic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may increase the tachycardiac effect of sympathomimetics
may increase the tachycardiac effect of sympathomimetics
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of anticholinergic agents
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the toxic effect of beta2 agonists
may increase the toxic effect of anticholinergic agents
may increase the toxic effect of anticholinergic agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the toxic effect of sympathomimetics
may increase the toxic effect of sympathomimetics
may increase the toxic effect of sympathomimetics
may increase the toxic effect of sympathomimetics
may increase the toxic effect of sympathomimetics
may increase the anticholinergic effect of anticholinergic agents
may decrease the cholinergic effect of cholinergic agents
Mechanism of action
aclidinium is a long-acting antimuscarinic agent (LAMA) used to treat chronic obstructive pulmonary disease (COPD). It works by blocking the action of acetylcholine, a neurotransmitter, on muscarinic receptors in the airways, leading to smooth muscle relaxation and increased airflow. This helps relieve symptoms such as coughing, wheezing, and shortness of breath in people with COPD.
On the other hand, formoterol is a long-acting beta2-adrenergic agonist (LABA) used to treat asthma and COPD. It stimulates beta2-receptors on airway smooth muscle, causing relaxation and increasing airflow. This helps relieve symptoms such as shortness of breath and wheezing.
Spectrum
The combination of aclidinium and formoterol results in a broad spectrum of activity for treating COPD, with antimuscarinic and bronchodilator effects. This helps improve airflow obstruction and reduce bronchoconstriction in patients with COPD
Frequency defined:
1-10%
Headache
Cough
Influenza
Insomnia
Dry mouth
Muscle spasms
Arthralgia
Urinary tract infections
Upper respiratory tract infections
Back pain
Sinusitis
Tooth abscess
Dizziness
Oropharyngeal pain
Musculoskeletal pain
Pain in extremity
Contraindications
aclidinium is contraindicated in individuals with hypersensitivity to the drug or its components. Additionally, its use is not recommended in patients with severe narrow-angle glaucoma, tachyarrhythmias, or urinary retention
formoterol is contraindicated in individuals with hypersensitivity to the drug or its components. It is also not recommended in patients with severe bronchospasms, such as asthma or chronic obstructive pulmonary disease (COPD), uncontrolled arrhythmias, or severe heart failure
Caution
aclidinium may cause side effects such as headache, nasopharyngitis, sinusitis, urinary tract infection, and dry mouth. It can also cause blurred vision, increased heart rate, and urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction.
formoterol may cause side effects such as tremors, headaches, palpitations, increased heart rate, and nervousness. In some cases, formoterol may worsen asthma symptoms, increase the risk of asthma-related hospitalization, and even cause life-threatening asthma episodes.
Both aclidinium and formoterol can interact with other medications and medical conditions. Patients should always inform their healthcare provider of all medications they are taking and any medical conditions they have before using these drugs
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
aclidinium is a long-acting muscarinic antagonist that works by blocking the action of acetylcholine on muscarinic receptors in the airways, leading to smooth muscle relaxation and increased air flow. formoterol, on the other hand, is a long-acting selective beta-2 agonist that works by stimulating beta2-receptors on airway smooth muscle, causing relaxation and increasing airflow. Both aclidinium and formoterol are used for the treatment of chronic obstructive pulmonary disease (COPD) and asthma to help relieve symptoms such as coughing, wheezing, and shortness of breath
Pharmacodynamics
aclidinium is a long-acting muscarinic antagonist (LAMA) that blocks the muscarinic receptors in the lungs. This results in the relaxation of airway smooth muscle, leading to improved lung function and reduced bronchoconstriction in individuals with chronic obstructive pulmonary disease (COPD)
formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that stimulates beta2-adrenergic receptors in the lungs. This leads to the relaxation of airway smooth muscle, resulting in improved lung function and relief of bronchoconstriction in individuals with asthma or COPD
When aclidinium and formoterol are combined, they work together to provide dual bronchodilation and improved lung function in individuals with COPD
Pharmacokinetics
Absorption: aclidinium is rapidly absorbed after inhalation, with peak plasma concentration achieved within 5 minutes. On the other hand, formoterol has a slower absorption rate, with peak plasma concentration achieved at 17 pg/mL
Distribution: The volume of distribution (Vd) of aclidinium is 300 L after an IV dose of 400 mcg. formoterol has a protein binding of 46% (RR enantiomer) and 58% (SS enantiomer) after inhalation of a 54 mcg dose
Metabolism: aclidinium is rapidly and extensively hydrolyzed in plasma to inactive derivatives. formoterol is primarily metabolized by direct glucuronidation and O-demethylation, followed by conjugation to inactive metabolites. CYP2D6 and CYP2C are identified as the main enzymes responsible for their O-demethylation
Elimination/Excretion: aclidinium has a half-life of approximately 12 hours and is excreted mainly through urine (54-65%) and feces (20-33%). formoterol is excreted mainly through urine (62%) and feces (24%)
Administration
aclidinium is available as an inhaled powder in a single-dose device and is used to treat chronic obstructive pulmonary disease (COPD). It works by relaxing the smooth muscles in the airways to improve breathing and reduce symptoms such as coughing, wheezing, and shortness of breath
formoterol, on the other hand, is a long-acting beta2-adrenergic agonist (LABA) that is used as a bronchodilator to treat asthma and COPD. It works by relaxing the smooth muscles in the airways, allowing for easier breathing. Formoterol is available as an inhaled powder or solution and may be used with other medications, such as corticosteroids, to manage symptoms of asthma or COPD
Patient information leaflet
Generic Name: aclidinium and formoterol
Pronounced: [ A-kli-DIN-ee-um-and-for-MOE-ter-ol ]
Why do we use aclidinium and formoterol?